Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors

ACR246 - Adcoris

ASN004 - Asana BioSci, Kirilys

SYD1875 - Byondis

PF-06263507 - Pfizer

X. Hu1; Y. Lu2; X. Wang2; Y. Huang2; F. Wang2; Y. Huang2

Jul 25, 2024